Therma Bright Announces Completion of Debt Settlements

February 16, 2018 9:01 AM EST | Source: Therma Bright Inc.

Toronto, Ontario--(Newsfile Corp. - February 16, 2018) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company, announces that further to its news release of January 17, 2018, it has now completed certain debt settlement transactions and issued an aggregate of 2,445,150 common shares to settle an aggregate of $244,515 debt.

The settled debt included the issuance to 125,000 shares to Rob Fia, CEO and a director of the Company to settle $12,500 debt; 200,000 shares to Joseph Heng, a director of the Company, to settle $20,000 debt; and 375,000 shares to Tak Wing Law, the Company's CFO, to settle $37,500 debt. The debt settlements with Messrs. Fia Heng and Law are related party transactions as defined in Multilateral Instrument 61-101- Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the formal valuation requirement and the shareholder approval requirement of MI 61-101.

All of the shares issued pursuant to the debt settlement are subject to a four month hold period expiring on June 17, 2018.

ABOUT THERMA BRIGHT:

Therma Bright is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Therma Bright's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.

Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Therma Bright received approval for the above claims from FDA (United States) in 1997.

Therma Bright Inc. trades on the (TSXV: THRM). For more information visit: www.thejenexcorporation.com or www.therozap.com.

For further information please contact:
Therma Bright Inc.
Rob Fia
CEO
rfia@thejenexcorporation.com

FORWARD LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

info